170 employees
Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express,
2016
$61M
from 4 investors over 4 rounds
Foghorn Therapeutics, Inc raised $61M on May 12, 2019
Investors: The Invus Group, Casdin Capital, LLC and Irving Investors
Foghorn Therapeutics, Inc raised $50M on March 13, 2018
Investors: Flagship Ventures